Preliminary Analysis of Solute Carrier Family in Nucleotide Rescue Synthesis in Glioma

Glioma is a highly proliferative and aggressive tumor type that arises from glial cells in the central nervous system. The nucleotides required for the proliferation and replication of glioma cells are crucial to their pathogenesis and often cannot be synthesized entirely de novo by tumor cells. These nucleotides must be taken up from the extracellular milieu to achieve the purpose of proliferation, a process that is mediated by solute carriers in the SLC28, SLC29, and SLC43 families. The expression of these solute carriers is linked to the proliferation of glioma cells, indicating their key role in glioma metabolism. Understanding the mechanisms underlying nucleotide transport and metabolism in gliomas may lead to the development of novel therapeutics that target these metabolic pathways and improve the prognosis for patients with glioma. Solute carrier family SLC28-, SLC29-, and SLC43-mediated nucleotide transport is involved in the proliferation of glioma and plays an important role in the proliferation and invasion of glioma. Among them, SLC43A3 is a potential biomarker for glioma proliferation, and the data presented here provide evidence for solute carrier involvement in glioma metabolism and construct a prognostic model.